

Closing remarks

Innovation & Growth: Progress with strategy

Pascal Soriot, Executive Director, Chief Executive Officer



Completing the first phase of the journey




Key messages

- ✓ Strategy implementation on track
- ✓ Building a sustainable, durable and more profitable business
- ✓ Pipeline value rapidly increasing
- ✓ Accelerating return to growth and ambition to become a >\$45bn company by 2023




AstraZeneca: A biopharmaceuticals leader



* IO = Immuno-oncology





Closing remarks

Innovation & Growth: Progress with strategy

Pascal Soriot, Executive Director, Chief Executive Officer